A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Inclusion criteria

• ✓. Participants who have histologically or cytologically documented advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, considered to be suitable for treatment with study intervention, as applicable to each substudy.
• ✓. Participants must provide sufficient archival or fresh tumour sample for biomarker testing.
• ✓. Life expectancy at the time of screening ≥ 12 weeks in the opinion of the Investigator.
• ✓. Measurable disease as per RECIST 1.1 criteria: at least one lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.
• ✓. ECOG PS of 0 to 1, with no deterioration over the previous 2 weeks prior to baseline at screening, and prior to study intervention administration.
• ✓. Adequate organ and marrow function.
• ✓. Participants must have histologically or cytologically confirmed newly diagnosed FIGO 2014 Stage III/IV epithelial ovarian\*, fallopian tube, or primary peritoneal cancer who are eligible for neoadjuvant treatment with planned IDS.
• ✓. Participants who are treatment-naïve.

Exclusion criteria